Hematologists near Hackensack, NJ

Biography: Jones Nauseef, M.D., Ph.D., is an Assistant Professor of Medicine within the Division of Hematology and Medical Oncology at Weill Cornell Medicine, and Assistant Attending physician at NewYork-Presbyterian Hospital. His clinical emphasis is on Genitourinary (GU) cancers and Phase I clinical trials. His research is focused on genomics of advanced prostate cancers, including neuroendocrine prostate cancer, as well as health care disparities.Dr. Nauseef received his B.A. in Biology in 2006 from Swarthmore College, where he also participated in NCAA Track and Cross Country. In 2015, Dr. Nauseef earned his M.D. and Ph.D. in Molecular Physiology and Biophysics (Laboratory of Dr. Michael D. Henry) as part of the NIH-sponsored MedicalScientist Training Program (MSTP) at the Carver College of Medicine of theUniversity of Iowa. He continued his medical training at Weill Cornell Medicine and NewYork-Presbyterian (WCM/NYP), where he completed his Internship and Residency in Internal Medicine in 2018. He was honored to be the recipient of the David B. Skinner award at the conclusion of his residency. He remained at WCM/NYP for his Fellowship in Hematology and Medical Oncology, during which time he was awarded a 2020 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) and the 2021 Scott Wadler Fellows Clinical Research Award. During his Fellowship, Dr. Nauseef expanded his research focus to include the genomics of advanced prostate cancers and health care disparities in American men of African descent. He serves as co-investigator or collaborator on extramural grants for the latter project. Dr. Nauseef will continue these investigations as a member of the Englander Institute for Precision Medicine and inaffiliation with the New York Genome Center, with the primary goal of leveraging discoveries to develop clinical trials as part of the Phase I/Earlytherapeutics group at Weill Cornell's Meyer Cancer Center.

Care Philosophy: Today's research and treatment of lung cancer are at the cutting edge of science and technology. Enormous progress has been made in lung cancer treatment. Several targeted therapies and now immunotherapies have changed the way we treat the disease. Cancer patients and their families who come to the Lombardi Comprehensive Cancer Center will work closely with a team of dedicated and knowledgeable cancer specialists to determine the most appropriate treatment path for their specific cancer needs. My research is focused on advancing our understanding of lung cancer and thymic tumors and their responses to specific treatment, including how to harness the body's immune system to fight cancer. I keep my patients and their families front and center in my practice to help them understand the technology that may be available to them. My goal is to always work together with my patients, using science to overcome disease.

Biography: Dr. Paul Pagnini has served as a leader in community-based and academic radiation oncology for the past 20 years. Dr. Pagnini completed his residency training in Radiation Oncology at Tufts/New England Medical Center where he was chief resident in his final year. He was awarded the prestigious Research Fellowship Award from the American Society of Therapeutic Radiation Oncology, which enabled him to study the role of intensity modulated radiation therapy (IMRT) for the treatment of cancers of the central nervous system. He has served on the Faculty of the University of Southern California, Keck School of Medicine where he was the Radiation Oncology Residency Program Director. His most recent position was with the Cleveland Clinic Florida, where he served as Department Chair for the last five years. He has multiple peer reviewed publications in the areas of intensity modulated radiation therapy (IMRT), 3-D conformal radiation therapy, Cyberknife, and Gamma-Knife radiosurgery.

Biography: Emily Tonorezos, MD MPH is a Clinical Associate Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital. Dr. Tonorezos received her bachelor's degree from Dartmouth College in Hanover, New Hampshire and her M.D. from the University of Rochester School of Medicine and Dentistry in 2001. Following Residency in Internal Medicine, she spent one year as Chief Resident in Internal Medicine, both at Columbia University Medical Center. She subsequently completed a General Internal Medicine fellowship at Johns Hopkins Hospital and Masters in Public Health at the Johns Hopkins Bloomberg School of Public Health. Dr. Tonorezos joined Weill Cornell from Memorial Sloan Kettering Cancer Center, where she served as Director of the Adult Long-Term Follow-Up Program for adult survivors of childhood and young adult cancers.

Biography: Dr. Peter Kozuch, MD is a Hematology Specialist who practices in New York, NY. He is 57 years old and has been practicing for 31 years. Dr. Peter Kozuch, MD is affiliated with Mount Sinai Hospital, Mount Sinai Morningside and Mount Sinai Queens.

Biography: Dr. Anupama Goel, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 28 years. Dr. Anupama Goel, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Charles Shapiro, MD is a Hematology Specialist who practices in New York, NY. He is 68 years old and has been practicing for 41 years. Dr. Charles Shapiro, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: I am a medical oncologist with interests in lung cancers, head and neck cancers, and pancreatic cancers. Its important to me that patients feel they are not alone in their fight against cancer. I have a strong interest in clinical trial and providing patients with the most advanced available care. My goal is to help patients be in control with their health and understand their treatment options.

Biography: Alana Nguyen, MD PhD, is an Assistant Professor in the Division of Hematology and Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital.Dr. Nguyen received her MD from Boston University in Boston, Massachusetts and herPhD from McGill University in Montreal, Canada. She went on to complete her postgraduate medical training in Internal Medicine at the Mount Sinai Hospital in New York City. After her residency, she entered fellowship training in Medical Oncology at Columbia University/New York-Presbyterian Hospital in the Physician-Scientist Pathway.Dr. Nguyen sees patients with malignancies of the digestive tract in her clinical practice.In addition, her research focuses on drug development based on biological understanding of therapy resistance. She received a Women Who Conquer Cancer Award from the American Society for Clinical Oncology and its Conquer Cancer Foundation for her work on a 3-dimensional culture model of patient tumors to predict for patients' response to chemotherapy and immunotherapy. Using this innovative model, her current research will focus on understanding the tumor microenvironment of pancreatic cancer, and how this tumor microenvironment participates in drug evasion.

Care Philosophy: nbsp; It takes a village to achieve the best care of patients in their battle against complicated blood disorders I am privileged to work in a world class medical institution which not only assures a multidisciplinary approach for patient treatment

Care Philosophy: My clinical interests include working with children with various blood disorders, such as sickle cell anemia, blood clotting disorders, and rare disorders called Myeloproliferative Neoplasms. I find it a privilege to be able to help families deal with their children's complex medical issues. By combining excellent, compassionate medical care with research aimed at improving outcomes and preventing disease-associated complications, I believe that we can make a difference for children with cancer and blood disorders.

Biography: Nora Chokr, M.D., is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/ NewYork-Presbyterian Hospital. She specializes in the care of patients with blood disorders who are in need of bone marrow or stem cell transplantation or cellular-based therapies, like chimeric antigen receptor (CAR) T-cell therapy. Dr. Chokr received her medical degree from the American University of Beirut Medical Center in Lebanon in 2015. She completed her Internal Medicine residency at Yale New Haven Hospital and her Hematology/Oncology fellowship at SUNY Downstate Medical Center, where she served as a Chief Fellow. Subsequently, she completed an advanced fellowship in Bone Marrow Transplantation and Immune Effector Cell Therapy at Weill Cornell Medicine (WCM)/NewYork-Presbyterian (NYP) Hospital. Upon completion of this advanced fellowship training, Dr. Chokr was recruited to join the faculty of the WCM/NYP Bone Marrow Transplantation Program. Dr. Chokr's main research interests focus on increasing transplant access and optimizing outcomes in older patients. Her interests also include the prevention of disease relapse and graft vs host disease after transplant. Dr. Chokr is an investigator for several clinical trials that aim to advance the field. She has publications in leading international peer-reviewed journals, and is a member of the American Society of Hematology (ASH), American Society for Transplantation and Cellular Therapy (ASTCT), ASTCT Aging Special Interest Group, Cancer and Aging Research Group (CARG). Dr. Chokr is also involved in teaching medical students, residents and fellows.

Biography: Juliet Barker, MBBS (Hons), FRACP, is an Australian trained hematologist. Having been an Attending Member and Physician at Memorial Sloan Kettering Cancer Center (MSKCC) and the Director of the MSKCC Cord Blood (CB) Transplantation Program, Dr. Barker has been recruited to Weill Cornell Medicine and NewYork-Presbyterian Hospital as the Director of the Bone Marrow Transplant and Cellular Therapy Program.Over the last 25 years, Dr. Barker has worked to expand transplant access to minority patients with hematologic malignancies and has demonstrated the ability of cord blood transplantation to provide curative therapy for such populations without suitable adult donors. Dr. Barker's work in this area has been internationally recognized and she has published extensively concerning novel strategies to optimize access to donor transplants and cord blood transplant outcomes. Additionally, she has a special focus on optimizing complex health care delivery such as hematopoietic stem cell transplantation in under-served populations. Dr. Barker has advised the National Marrow Donor Program (NMDP) and is a member of the Advisory Council on Blood Stem Cell Transplantation to the Health Resources and Services Administration of the U.S. government. She has served on the American Society for Transplantation and Cellular Therapy (ASTCT) Board and led the national ASTCT Cord Blood Special Interest Group. Having previously served as Associate Vice Chair, Faculty Development, in the Department of Medicine at MSKCC, Dr. Barkeralso has a keen interest in academic mentorship.

Care Philosophy: My philosophy is simple: the patient comes first. As part of the Genitourinary Oncology Program at Weill Cornell Medicine, I am committed to delivering the best care to my patients. Our world-class multidisciplinary team ensures that we treat the patient as a whole, not just the cancer. I am driven by the desire to improve therapy of urological malignancies by identifying the genetic "Achilles heel" of each patient's cancer. Through my research, I am committed to developing "precision medicine" approaches and conducting clinical trials for treatment of bladder cancer and other genitourinary malignancies.

Biography: Rohit K. Jain MD, MPH is an Associate Professor of Medicine at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian Hospital- Weill Cornell Medical Center. Dr. Jain earned his medical degree at Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India. He completed Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore and Hematology-Oncology Fellowship at Roswell Park Cancer Institute University at Buffalo, New York. After fellowship, Dr. Jain, joined the H. Lee Moffitt Cancer Center in Tampa, Florida as Assistant Professor, and was instrumental in building the bladder cancer program. Dr. Jain was selected as Castle Connolly "Top Doctor" for 2024, as well as one of America's Best Prostate Cancer Oncologist by Newsweek magazine in 2024. Dr. Jain was recruited to Weill Cornell Medicine (WCM) in 2024. He cares for patients with bladder (urothelial), kidney (renal), prostate and testicular cancers, with a major focus in urothelial cancers. His research interests are primarily in urothelial and prostate cancers. Dr. Jain is involved in biomarker research as well as developing innovative clinical trials for patients, and he has received funding from the National Cancer Institute (NCI).

Biography: Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and other bone marrow disorders. Dr. Assal completed his medical education and internal medicine training at NYU School of Medicine. He was also a hospitalist in the department of medicine at Memorial Sloan Kettering Cancer Center caring for patients with a variety of cancer diagnoses, including stem cell transplant patients. Dr. Assal completed a fellowship in hematology and medical oncology at Albert Einstein College of Medicine where he also served as chief fellow. He finally completed a fellowship in blood and marrow stem cell transplantation at Memorial Sloan Kettering Cancer Center. His research interests center around improving outcomes of stem cell transplantation and the diseases it is used to treat. He has a particular interest in immunotherapy and studying ways to harness the immune system to attack tumor cells, while at the same time decreasing the risk of graft versus host disease. He is also interested in studying therapeutic interventions to prevent and treat relapse of disease after stem cell transplantation. He has presented his research at several national conferences and was awarded an American Society of Hematology Abstract Achievement award for his research.

Biography: Michal Bar-Natan, MD, is Interim Assistant Professor of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City.Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health.In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women's Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia programat the Mt. Sinai Tisch Cancer Institute.Dr. Bar-Natan's focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.

Biography: Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Children's Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for it's leadership in the treatment of patients with lymphoma. Dr. Roth's research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth

Biography: Sarah Schneider, NP is a Hematology Specialist who practices in New York, NY. Sarah Schneider, NP is affiliated with Weill Cornell Medical Center.

Biography: Dr. Rosenzweig is an Assistant Professor in the Department of Pediatrics at Weill Cornell Medicine and an Assistant Attending Pediatrician at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Rosenzweig completed her undergraduate work at Emory University. She received her medical degree from the University of Miami Miller School of Medicine. She conducted her residency in Pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center and her fellowship in pediatric hematology/oncology at the joint program at Memorial Sloan Kettering Cancer Center and NewYork-Presbyterian-Weill Cornell Medical Center. She is board certified in General Pediatrics and Pediatric Hematology/Oncology.Dr. Rosenzweig specializes in treating children and adolescents with leukemia and lymphoma, including acute lymphoblastic leukemia, acute myelogenous leukemia, Hodgkin lymphoma and Non-Hodgkin lymphoma.Dr. Rosenzweig's clinical and research interests lie in identifying new treatments for children with leukemia. She is particularly interested in identifying novel targeted therapies. She is a member of the Children's Oncology Group.

Biography: Dr. Gulati obtained her medical degree from Seth G.S. Medical College and K.E.M. Hospital in Mumbai, India, followed by a pediatrics residency at SUNY Downstate Medical center. She completed my pediatric hematology/oncology fellowship at the joint program between New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. She then went on to complete a year of specialized training in Pediatric lymphoma and Histiocytosis at Baylor College of Medicine/Texas Children's Hospital Cancer and Hematology Centers in Houston, Texas. Dr. Gulati subsequently joined the lymphoma and histiocytosis team as an Assistant professor and worked there between 2019-2023.Dr. Gulati's research and clinical interests focus on identifying pathogenic mechanisms of pediatric lymphoma and histiocytosis through collaborative and comprehensive research projects that look at the histologic, molecular, and genomic features of these diseases with the ultimate goal of identifying potential novel therapeutic targets.Dr. Gulati is an active member of the pediatric non-Hodgkin lymphoma committee of the children's oncology group and serves as the vice-chair on the upcoming first of its kind trial for relapsed L.C.H. conducted by the C.O.G. She is an active member of the North American Consortium for Histiocytosis (NACHO) and a steering committee member of the INTO-HLH.

Biography: Nicholas Cacciola-Price, NP is a Radiation Oncology Specialist who practices in New York, NY. Nicholas Cacciola-Price, NP is affiliated with Newyork-Presbyterian.

Biography: CERTIFICATIONS AND CREDENTIALS:Advanced Oncology Certified Nurse (AOCN)Advanced Nurse Practitioner, Board Certified (ANP-C)

Biography: Dr. Mateo Mejia is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital.Dr. Mejia received his medical degree (M.D.) from the Universidad CES in his hometown of Medellin, Colombia, after which he completed an internal medicine residency at the Jacobi Medical Center/Albert Einstein College of Medicine in the Bronx, NY, where he also served as a Chief Resident. He completed his Hematology and Oncology fellowship at Weill Cornell Medicine/NewYork-Presbyterian Hospital and joined the Hematology and Medical Oncology Division after completing his fellowship training in 2023. During fellowship, Dr. Mejia developed his clinical experience under the mentorship of Dr. Ruben Niesvizky, while pursuing his laboratory research at Dr. Mark Bustoros' Laboratory, being able to complete both clinical and translational research in the plasma cell malignancy field.Dr. Mejia's research has focused on the genomic drivers of aggressive forms of myeloma, for which he received the 2022 Conquer Cancer American Society of Clinical Oncology (ASCO) Young Investigator Award, a prestigious honor only given to 100 of people each year. Additionally, Dr. Mejia was the recipient ofthe 2022 Charles, Lillian and Betty Neuwirth Foundation Fellowship in Oncology award for his project "Genomic Landscape of Multiple Myeloma with Extramedullary Disease". Dr. Mejia's research also investigates the connectionof race, ethnicity and myeloma, how myeloma escapes the surveillance of the immune system, as well as how genetic information can be used to develop novel approaches to treat myeloma.

Care Philosophy: I believe that it is a privilege to take care of patients who have cancer. Patients deserve to be treated with care and respect. I give my patients the time they need to discuss all of their concerns, without rushing them. My patients have access to my personal cell phone number. Staying current on all of the latest clinical research is important to me, as is collaboration with subspecialists in order to ensure the best possible care.

Biography: Dr. Jorge Gomez, MD is a Hematology Specialist who practices in New York, NY. He is 63 years old and has been practicing for 37 years. Dr. Jorge Gomez, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Joshua Brody, MD is a Hematology Specialist who practices in New York, NY. He is 51 years old and has been practicing for 25 years. Dr. Joshua Brody, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Ronald Hoffman, MD is an Anatomic /amp Clinical Pathology Specialist who practices in New York, NY. He is 80 years old and has been practicing for 54 years. Dr. Ronald Hoffman, MD is affiliated with Mount Sinai Hospital.